Get it on Google Play

Vera Therapeutics receives FDA priority review for IgA nephropathy drug

January 7, 2026 7:30 AM EST Send to a Friend
Vera Therapeutics Inc (NASDAQ: VERA) announced that the U.S. Food and Drug Administration granted priority review to its biologics license ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login